Omeros announces first commercial sales of Yartemlea

Omeros (OMER) Corporation announced that the first commercial shipments of Yartemlea to its distributors were completed last week, with orders from transplant centers beginning that same day. Both adult and pediatric patients with stem cell transplant-associated thrombotic microangiopathy, or TA-TMA, are now receiving Yartemlea, including patients who have recently failed prior off-label C5-inhibitor regimens. Yartemlea, which was approved by the U.S. FDA on December 23, 2025, is the first and only approved therapy for TA-TMA. A marketing authorization application for Yartemlea for the treatment of TA-TMA is currently under review by the European Medicines Agency with a decision expected in mid-2026.